

# Shinya Rai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9062503/publications.pdf>

Version: 2024-02-01

38  
papers

969  
citations

933447

10  
h-index

477307

29  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1198  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Nonâ€“Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	1.6	388
2	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
3	A multicenter, openâ€“label, phase II study of tirabrutinib (ONO/GSâ€“4059) in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. <i>Cancer Science</i> , 2020, 111, 3327-3337.	3.9	60
4	The Clathrin Assembly Protein PICALM Is Required for Erythroid Maturation and Transferrin Internalization in Mice. <i>PLoS ONE</i> , 2012, 7, e31854.	2.5	47
5	Phase II study of tazemetostat for relapsed or refractory Bâ€“cell nonâ€“Hodgkin lymphoma with EZH2 mutation in Japan. <i>Cancer Science</i> , 2021, 112, 3627-3635.	3.9	32
6	Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells. <i>Cells</i> , 2019, 8, 226.	4.1	25
7	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large Bâ€“cell lymphoma. <i>Cancer Science</i> , 2021, 112, 2845-2854.	3.9	24
8	Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. <i>International Journal of Hematology</i> , 2017, 106, 691-703.	1.6	19
9	Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. <i>Nature Communications</i> , 2020, 11, 4147.	12.8	15
10	Twoâ€“year outcomes of tirabrutinib monotherapy in WaldenstrÃ¶mâ€™s macroglobulinemia. <i>Cancer Science</i> , 2022, 113, 2085-2096.	3.9	15
11	Clathrin Assembly Protein CALM Plays a Critical Role in KIT Signaling by Regulating Its Cellular Transport from Early to Late Endosomes in Hematopoietic Cells. <i>PLoS ONE</i> , 2014, 9, e109441.	2.5	11
12	Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. <i>Leukemia Research Reports</i> , 2020, 14, 100219.	0.4	6
13	Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality. <i>Frontiers in Immunology</i> , 2018, 9, 3031.	4.8	5
14	Tumourâ€“immune microenvironment in duodenalâ€“type follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 243-252.	2.5	5
15	Decreased expression of Tâ€“cellâ€“associated immune markers predicts poor prognosis in patients with follicular lymphoma. <i>Cancer Science</i> , 2021, , .	3.9	5
16	The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, LBA-1-LBA-1.	1.4	5
17	Epsteinâ€“Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy. <i>Viruses</i> , 2020, 12, 416.	3.3	4
18	Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 303-303.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. <i>International Journal of Hematology</i> , 2021, 114, 205-216.	1.6	3
20	The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia. <i>Internal Medicine</i> , 2020, 59, 2745-2749.	0.7	3
21	Two-Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2021, 138, 1352-1352.	1.4	2
22	Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. <i>Cancers</i> , 2018, 10, 304.	3.7	2
23	Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Young Patient with Richter Syndrome Presenting with Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma with Different Cell Origins. <i>Internal Medicine</i> , 2013, 52, 273-276.	0.7	1
24	Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome. <i>British Journal of Haematology</i> , 2019, 184, 122-122.	2.5	1
25	Antidiuretic hormone and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. <i>British Journal of Haematology</i> , 2019, 184, 121-121.	2.5	1
26	Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome. <i>Annals of Hematology</i> , 2020, 99, 381-383.	1.8	1
27	Antiretroviral Therapy Improves Acquired Immunodeficiency Syndrome with Systemic Lupus Erythematosus. <i>Life</i> , 2021, 11, 463.	2.4	1
28	Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma. <i>Blood</i> , 2021, 138, 1345-1345.	1.4	1
29	C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis. <i>International Journal of Hematology</i> , 2022, 115, 310.	1.6	1
30	CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence. <i>International Journal of Hematology</i> , 2022, 115, 336-349.	1.6	1
31	Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells. <i>British Journal of Haematology</i> , 2022, 198, 360-372.	2.5	1
32	Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 507-509.	1.3	0
33	Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation. <i>Leukemia Research Reports</i> , 2021, 15, 100256.	0.4	0
34	VII. Pathological Mechanism and Treatment of Therapy-related AML. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 1316-1323.	0.0	0
35	Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. <i>Cancers</i> , 2018, 10, .	3.7	0
36	Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases. <i>Blood</i> , 2021, 138, 4523-4523.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
38	Asia subpopulation analysis from the phase III POLARIX trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7558-7558.	1.6	0